Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVADE: Myeloid Suppressive Cells in AML/MDS Relapse
NCT03964922Unknown
- Sponsor
- CHRU de Nancy - Hôpital Central
- Start
- Sep 2019
- Primary completion
- Jun 2022
01
Overview
Single-arm trial, sponsored by CHRU de Nancy - Hôpital Central. Primary endpoint: Myeloid suppressive cells and relapse incidence at 2 years. Status: unknown.
Beyond the preview
Go deeper on NCT03964922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03964922.